Dr. Rendell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
The Rose Salter Medical Research Foundation
34 Versailles
Newport Beach, CA 92657Phone+1 949-813-4026Fax+1 888-589-6967
Education & Training
University of Miami/Jackson Health SystemFellowship, Endocrinology, Diabetes, and Metabolism, 1976 - 1977
University of ConnecticutResidency, Internal Medicine, 1975 - 1976
Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalInternship, Internal Medicine, 1972 - 1973
State University of New York Downstate Medical Center College of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1977 - 2026
NE State Medical License 1986 - 2026
NV State Medical License 1989 - 2025
MD State Medical License 1973 - 2005
OK State Medical License 1983 - 1993
FL State Medical License 1976 - 1981- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013
Clinical Trials
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
- Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Jan 01
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria Start of enrollment: 2013 Oct 01
Publications & Presentations
PubMed
- 273 citationsPioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled studyDaniel Einhorn, Marc Rendell, James L. Rosenzweig, John W. Egan, Annette L. Mathisen
Clinical Therapeutics. 2000-12-01 - 132 citationsTargeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trialMark R. Rigby, Linda A. DiMeglio, Marc Rendell, Eric I. Felner, Jean M. Dostou
The Lancet. Diabetes & Endocrinology. 2013-12-01 - 76 citationsEffect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study.D.Eugene Strandness, Ronald L. Dalman, Steve Panian, Marc Rendell, Peter Zhang
Vascular and Endovascular Surgery. 2002-03-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
